Aspen signs off on GSK drug transaction | Fin24
 
  • Data Market Inquiry

    MTN says it is prepared to defend itself before Competition Tribunal over report.

  • Claims of sabotage

    What we know so far about allegations of sabotage at an Eskom power station.

  • Dudu Myeni

    Court dismisses former SAA chiar's bid to have Outa withdraw from delinquency case.

Loading...

Aspen signs off on GSK drug transaction

Mar 01 2017 16:33
needle


Company Data

ASPEN PHARMACARE HOLDINGS LIMITED [JSE:APN]

Last traded 111
Change 0
% Change 0
Cumulative volume 1979406
Market cap 0

Last Updated: 01/01/0001 at 12:00. Prices are delayed by 15 minutes. Source: McGregor BFA

Related Articles

Aspen sinks to four-month low as volumes surge after Glaxo sells

Glaxo sells stake in SA's Aspen for R8.47bn

Aspen targets further Chinese acquisitions

Aspen continues spending spree with $372m purchase

Aspen heads for biggest decline in 17 years

Aspen expands in China as it targets global growth

 

Cape Town - South Africa's biggest generic drug maker Aspen Pharmacare [JSE:APN] signed off on an agreement with GlaxoSmithKline to acquire a portfolio of anaesthetics, the company reported on Wednesday.

The company will pay an initial amount of £180m, paying an added £100m if certain goals are met in the three years following completion, according to a statement issued on Wednesday.

READ: Aspen continues spending spree with $372m purchase

The transaction was completed on February 28 2017 on a global scale and on a national scale in Durban on March 1 2017. The deal adds to the anaesthetics Aspen bought in June from AstraZeneca of the UK for as much as $770m.

Aspen's shares declined 0.21% to R282.78 as of 16:32 on the Johannesburg Stock Exchange.

Read Fin24's top stories trending on Twitter:

aspen pharmacare  |  health  |  companies
NEXT ON FIN24X

 
 
 
 

Company Snapshot

Voting Booth

How concerned are you about ransomware attacks?

Previous results · Suggest a vote

Loading...